Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 14/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462209 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2460843 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL203904 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL203905 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2329779 | 0.95 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL4704983 | 0.95 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2462379 | 0.95 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL7327118 | 0.93 | CCR2 (0.57) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL7327122 | 0.93 | CCR2 (0.57) | CCR2GAACCR1CCR5CXCR4 | |
| Acetic Acid SCHEMBL8778037 | 0.92 | CCR2 (0.62) | CCR2GAACCR1CCR5CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025030117-A1 | FERROPTOSIS INDUCERS | ARPEGGIO BIOSCIENCES, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-3986903-B1 | BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-10 | — | — | EP | disclosed |
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220298186-A1 | BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-09-22 | — | — | US | disclosed |
| EP-3986903-A1 | BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | CCR2 2097/4885GAA 1724/4885CCR1 2374/4885 |
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | CCR2 13/4885GAA 4579/4885CCR1 81/4885 |
| US-20220298186-A1 | BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS | FPR1, FPR2, FPR3 | CCR2 55/4885GAA 4489/4885CCR1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.